Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung CancerYi‐Long Wu, Roy S. Herbst, Masahiro Tsuboi et al.|New England Journal of Medicine|2020Cited by 1.7k
Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLCMasahiro Tsuboi, Yi‐Long Wu, Thomas John et al.|New England Journal of Medicine|2023Cited by 605
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trialsAlexander Drilon, Robert C. Doebele, Salvatore Siena et al.|The Lancet Oncology|2019Cited by 537
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA TrialRoy S. Herbst, Masahiro Tsuboi, Yi‐Long Wu et al.|Journal of Clinical Oncology|2023Cited by 386
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based ChemotherapyHelena A. Yu, Pasi A. Jänne, Yasushi Goto et al.|Journal of Clinical Oncology|2023Cited by 224